Earnings call transcript: Crexendo Q4 2025 posts solid growth By Investing.com

Crexendo reported Q4 2025 EPS of $0.09 vs. $0.08 consensus (12.5% beat) and revenue of $18.1M, a slight miss vs. $18.14M (-0.22%). Full-year 2025 revenue was $68.2M (+12% YoY) with GAAP net income $5.1M (vs. $1.7M in 2024) and year-end cash of $31.4M (+72% YoY). Management closed an acquisition of Estech Systems (ESI) for $35M ( $27.3M cash + $7.7M stock), expects it to be accretive, and guided FY2026 EPS $0.39 on $97M revenue and FY2027 EPS $0.49 on $109.85M revenue; shares rose ~0.94% after-hours to $6.47.

Analysis

Crexendo’s deal-driven playbook materially changes the competitive map in SMB UCaaS: the acquisition accelerates scale, concentrates recurring revenue, and reduces marginal CAC for future licensee wins. Second-order winners include cloud infra providers (OCI) where migration yields outsized cost saves, and Master-Agents/AppDirect-type distributors that can monetize expanded product bundles. Conversely, legacy vendors with heavy on-prem footprints will feel renewed pressure on pricing and retention as bundled AI services become table stakes.

Margin upside is realistically front-loaded and operationally tractable — data-center consolidation and licensing rationalization should drive leverage within the next 2–4 quarters if execution stays clean. The main near-term risk is integration execution (audit surprises, customer attrition, or slower-than-expected OCI migration), which would push synergy realization into a multi-quarter timeline and compress consensus multiples. Key monitoring items: audited pro-forma statements, churn/NRR trends at acquired accounts, and timing of OCI-related opex declines.

The AI stack (CAIRO + partner marketplace) is the highest-conviction organic growth lever but is adoption-dependent: it can lift ARPA meaningfully if licensing and attachment rates with existing licensees accelerate, yet regulation/voice-compliance and customer inertia can throttle revenue conversion. Expect a 6–18 month runway for CAIRO to materially show up in reported ARPA and services gross margin. Sentiment is already optimistic; the market will re-rate on tangible proof points (quarterly synergy capture, AI monetization cadence).

Key Decisions for Investors

• Long CXDO equity (size: 2–4% portfolio) — entry: current market; horizon: 6–12 months. Thesis: acquisition + AI monetization re-rate; target: +40–60% if audited pro-forma confirms accretion and first-quarter post-close synergies. Tactical stop: 20% below entry to limit execution/integration risk.
• Buy a defined-risk options spread on CXDO to amplify upside while capping premium loss — e.g., buy 9–12 month call spread (near-ATM / modest OTM). Rationale: limited downside (premium) vs 2x–4x upside if CAIRO adoption and ESI synergies accelerate within a year. Close or roll if audited filings miss expectations.
• Relative-value pair: long CXDO / short EGHT (8x8) equal notional for 3–9 months. Rationale: small-cap consolidator with improving FCF and AI monetization vs larger incumbent facing secular headwinds; target spread widening of 25–40% (relative performance). Risk: EGHT outperforms on independent product wins or macro recovery—tighten stop if pair underperforms by 15%.
• Event-trigger leg: small long position ahead of audited ESI 10-K, add into strength if pro-forma margins validated. If audit reveals shortfalls, trim immediately and redeploy into AI adoption call spreads — this preserves optionality around the single largest binary catalyst.
• Contrarian hedge: buy short-dated puts on a large UCaaS incumbent (e.g., RNG) sized at 25–50% of CXDO position cost to protect against sector derating from regulatory or macro-driven SMB spend pullback over the next 3–6 months.